Unresectable Extrahepatic Bile Duct Cancer Completed Phase 2 Trials for Selumetinib (DB11689)

IndicationStatusPhase
DBCOND0028791 (Unresectable Extrahepatic Bile Duct Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00553332Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By SurgeryTreatment